Breaking News

Ligand Earns Milestone for Kyprolis Sales

By Kristin Brooks | February 11, 2014

Receives $1 million commercial milestone payment from Onyx

Ligand Pharmaceuticals, Inc. has earned $1 million commercial milestone payment from Onyx Pharmaceuticals, a subsidiary of Amgen, triggered by the achievement of more than $250 million of annual product sales of Kyprolis in 2013.
Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones. Kyprolis is indicated to treat multiple myeloma and was received accelerated approval from FDA in July 2012.
blog comments powered by Disqus
  • Halo/Altus Q&A

    Halo/Altus Q&A

    Gil Roth||June 12, 2013
    Halo's CEO discusses his recent formulation partnership

  • Quintiles Q&A

    Quintiles Q&A

    Kristin Brooks||June 5, 2013
    Discussing a new partnership with Merck Serono